206 related articles for article (PubMed ID: 38170620)
1. The evolving landscape of antibody-drug conjugates in ovarian cancer: new drugs for a new era.
García-Illescas D; Mazzeo R; García-Durán C; Oaknin A
Curr Opin Obstet Gynecol; 2024 Apr; 36(2):104-111. PubMed ID: 38170620
[TBL] [Abstract][Full Text] [Related]
2. Next-generation antibody-drug conjugates for breast cancer: Moving beyond HER2 and TROP2.
Schlam I; Moges R; Morganti S; Tolaney SM; Tarantino P
Crit Rev Oncol Hematol; 2023 Oct; 190():104090. PubMed ID: 37562695
[TBL] [Abstract][Full Text] [Related]
3. Advances in antibody-drug conjugates for gynecologic malignancies.
Tymon-Rosario J; Gorman M; Richardson DL; Washington C; Santin AD
Curr Opin Obstet Gynecol; 2023 Feb; 35(1):6-14. PubMed ID: 36484278
[TBL] [Abstract][Full Text] [Related]
4. Implementing antibody-drug conjugates (ADCs) in HER2-positive breast cancer: state of the art and future directions.
Ferraro E; Drago JZ; Modi S
Breast Cancer Res; 2021 Aug; 23(1):84. PubMed ID: 34380530
[TBL] [Abstract][Full Text] [Related]
5. Antibody-Drug Conjugates in Gynecologic Cancers.
Anastasio MK; Shuey S; Davidson BA
Curr Treat Options Oncol; 2024 Jan; 25(1):1-19. PubMed ID: 38172449
[TBL] [Abstract][Full Text] [Related]
6. Antibody-drug conjugates for the treatment of ovarian cancer.
Calo CA; O'Malley DM
Expert Opin Biol Ther; 2021 Jul; 21(7):875-887. PubMed ID: 32463296
[TBL] [Abstract][Full Text] [Related]
7. Antibody-drug conjugates in cancer therapy: innovations, challenges, and future directions.
Kumari S; Raj S; Babu MA; Bhatti GK; Bhatti JS
Arch Pharm Res; 2024 Jan; 47(1):40-65. PubMed ID: 38153656
[TBL] [Abstract][Full Text] [Related]
8. Antibody drug conjugates as targeted cancer therapy: past development, present challenges and future opportunities.
Maiti R; Patel B; Patel N; Patel M; Patel A; Dhanesha N
Arch Pharm Res; 2023 May; 46(5):361-388. PubMed ID: 37071273
[TBL] [Abstract][Full Text] [Related]
9. The evolving landscape of antibody-drug conjugates in gynecologic cancers.
Tolcher A; Hamilton E; Coleman RL
Cancer Treat Rev; 2023 May; 116():102546. PubMed ID: 37023499
[TBL] [Abstract][Full Text] [Related]
10. Antibody-drug conjugates for ovarian cancer: current clinical development.
Stewart D; Cristea M
Curr Opin Obstet Gynecol; 2019 Feb; 31(1):18-23. PubMed ID: 30531606
[TBL] [Abstract][Full Text] [Related]
11. Integrating antibody drug conjugates in the management of gynecologic cancers.
Chelariu-Raicu A; Mahner S; Moore KN; Lorusso D; Coleman RL
Int J Gynecol Cancer; 2023 Mar; 33(3):420-429. PubMed ID: 36878560
[TBL] [Abstract][Full Text] [Related]
12. Antibody-Drug Conjugates: The New Frontier of Chemotherapy.
Ponziani S; Di Vittorio G; Pitari G; Cimini AM; Ardini M; Gentile R; Iacobelli S; Sala G; Capone E; Flavell DJ; Ippoliti R; Giansanti F
Int J Mol Sci; 2020 Jul; 21(15):. PubMed ID: 32752132
[TBL] [Abstract][Full Text] [Related]
13. Antibody-Drug Conjugates (ADCs) for Personalized Treatment of Solid Tumors: A Review.
Lambert JM; Morris CQ
Adv Ther; 2017 May; 34(5):1015-1035. PubMed ID: 28361465
[TBL] [Abstract][Full Text] [Related]
14. Antibody Drug Conjugates in the Treatment of Epithelial Ovarian Cancer.
Richardson DL; Seward SM; Moore KN
Hematol Oncol Clin North Am; 2018 Dec; 32(6):1057-1071. PubMed ID: 30390760
[TBL] [Abstract][Full Text] [Related]
15. Progress in Gynecologic Cancers with Antibody Drug Conjugates.
O'Malley DM; Calo CA
Curr Oncol Rep; 2021 Jun; 23(8):89. PubMed ID: 34125311
[TBL] [Abstract][Full Text] [Related]
16. The target invites a foe: antibody-drug conjugates in gynecologic oncology.
Campos MP; Konecny GE
Curr Opin Obstet Gynecol; 2018 Feb; 30(1):44-50. PubMed ID: 29227302
[TBL] [Abstract][Full Text] [Related]
17. Evolving Landscape of Antibody Drug Conjugates in Lymphoma.
Prakash R; Subbiah V; Iyer SP
Cancer J; 2022 Nov-Dec 01; 28(6):479-487. PubMed ID: 36383911
[TBL] [Abstract][Full Text] [Related]
18. Recent Advances in Antibody-Drug Conjugates for Breast Cancer Treatment.
Deng S; Lin Z; Li W
Curr Med Chem; 2017; 24(23):2505-2527. PubMed ID: 28554322
[TBL] [Abstract][Full Text] [Related]
19. The next generation of antibody drug conjugates.
Mack F; Ritchie M; Sapra P
Semin Oncol; 2014 Oct; 41(5):637-52. PubMed ID: 25440608
[TBL] [Abstract][Full Text] [Related]
20. Synthesis, characterization and targeting chemotherapy for ovarian cancer of trastuzumab-SN-38 conjugates.
Yao Y; Yu L; Su X; Wang Y; Li W; Wu Y; Cheng X; Zhang H; Wei X; Chen H; Zhang R; Gou L; Chen X; Xie Y; Zhang B; Zhang Y; Yang J; Wei Y
J Control Release; 2015 Dec; 220(Pt A):5-17. PubMed ID: 26439663
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]